Meliglix 100 Mg

Sitagliptin Hydrochloride, the active ingredient in Meliglix 100 Mg, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a 100 mg tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive diabetes treatment plan.

GNH USA supplies Meliglix 100 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity across markets and providing reliable logistics support for timely delivery.

Meliglix (sitagliptin) is used to improve glycaemic control in the type 2 diabetes therapeutic pathway. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Monotherapy in patients unsuitable for metformin: provides effective glucose reduction as a single oral agent. - Combination therapy with other antidiabetics: enhances overall glycaemic control when added to agents such as sulfonylureas or insulin.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient, mild to moderate intensity. - Upper respiratory tract infection: symptoms of cough, sore throat, or congestion. - Nausea: occasional mild gastrointestinal upset.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or jaundice. - Joint pain: unexplained arthralgia that may be persistent.

When prescribing or dispensing Meliglix, consider the following safety measures. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes regularly. - History of pancreatitis: avoid use or discontinue promptly if symptoms recur. - Concomitant insulin or sulfonylureas: monitor for hypoglycaemia. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Sitagliptin may interact with other medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Duplicate DPP‑4 inhibition: concurrent use with another DPP‑4 inhibitor can lead to excessive drug exposure. - Strong CYP3A4 inhibitors: may increase sitagliptin plasma levels, requiring caution.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia, necessitating dose adjustments. - Diuretics causing dehydration: may affect renal clearance of sitagliptin. - Rifampin: may reduce sitagliptin effectiveness by inducing metabolism.